Duke vaccine extends survival for patients with deadly brain cancers
DURHAM, N.C. -- A new vaccine added to standard therapy appears to offer a survival advantage for patients suffering from glioblastoma (GBM), the most deadly form of brain cancer, according to a study from researchers at Duke University Medical Center and The University of Texas MD Anderson Cancer Center.
The vaccine also knocks out a troublesome growth factor that characterizes the most aggressive form of the disease.
"About a third of all glioblastomas are fueled by a very aggressive cancer gene, called EGFRvIII; these tumors are the 'worst of the worst,'" said John ...

